U.S. Health Care REITs Stock News

NYSE:TGLS
NYSE:TGLSBuilding

Undervalued Small Caps With Insider Buying Opportunities In May 2026

The United States market has shown robust performance recently, with a 3.2% increase over the last week and a remarkable 31% rise over the past year, while earnings are expected to grow by 16% annually. In this thriving environment, identifying small-cap stocks that may be undervalued and exhibit insider buying can present unique opportunities for investors seeking potential growth in their portfolios.
NasdaqCM:CXDO
NasdaqCM:CXDOIT

High Growth Tech Stocks to Watch in the US May 2026

The United States market has shown a robust performance, climbing 3.2% in the last week and up 31% over the past year, with earnings forecasted to grow by 16% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability to capitalize on these favorable market conditions.
NasdaqGS:FFBC
NasdaqGS:FFBCBanks

Top Dividend Stocks To Consider In May 2026

The United States market has shown robust growth, climbing 3.2% in the past week and an impressive 31% over the last year, with earnings projected to grow by 16% annually. In such a dynamic environment, dividend stocks that offer both reliable income and potential for capital appreciation can be particularly appealing to investors seeking stability amidst market fluctuations.
NasdaqGS:EXEL
NasdaqGS:EXELBiotechs

Exelixis (EXEL) Margin Expansion To 35.1% Challenges Bearish Pricing Narratives

Exelixis (EXEL) opened 2026 with Q1 revenue of US$610.8 million and basic EPS of US$0.81, setting a clear marker for how the year is starting to shape up. The company has seen quarterly revenue move from US$555.4 million in Q1 2025 to US$610.8 million in Q1 2026, while basic EPS over that same span shifted from US$0.57 to US$0.81. This is prompting investors to focus on how sustained profitability and margins might influence sentiment around the latest numbers. See our full analysis for...